Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tevogen Bio Holdings is a pre-revenue clinical-stage biotechnology company developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers. The company's lead programs target COVID-19, Epstein-Barr virus, and oncology indications using its ExacTcell platform technology. With no commercial products, negative operating cash flow of approximately $30M annually, and a current ratio of 0.31, the company faces significant near-term financing risk.
Tevogen is developing allogeneic (off-the-shelf) T-cell therapies that do not require genetic modification, potentially offering faster manufacturing and lower costs versus CAR-T competitors. The ExacTcell platform aims to identify and expand virus-specific T-cells from healthy donors for use across multiple patients. Revenue generation depends entirely on successful clinical trials (Phase I/II stage as of early 2026), FDA approval (likely 3-5+ years away), and commercialization. The company has no pricing power currently and burns cash to fund R&D and clinical operations. Competitive advantage hinges on demonstrating clinical efficacy, safety profile superior to existing therapies, and manufacturing scalability.
Clinical trial data releases and regulatory milestone announcements (IND filings, Phase advancement, safety/efficacy readouts)
Capital raises and financing announcements (dilutive equity offerings, debt facilities, strategic partnerships)
Competitive developments in allogeneic T-cell therapy space (rival trial results, FDA approvals for competing platforms)
Management changes, patent developments, or manufacturing partnership announcements
Broader biotech sector sentiment and risk appetite for pre-revenue clinical assets
Clinical trial failure risk - Phase I/II assets have <15% probability of ultimate FDA approval; single negative readout could render equity worthless
Regulatory pathway uncertainty for allogeneic T-cell therapies with evolving FDA guidance on manufacturing, potency assays, and safety monitoring requirements
Reimbursement uncertainty - even with approval, payer willingness to cover novel cell therapies at profitable price points remains unproven for non-CAR-T approaches
Intense competition from well-funded CAR-T leaders (Gilead/Kite, BMS/Juno, Novartis) and allogeneic platforms (Allogene, Atara Biotherapeutics) with deeper pipelines and manufacturing scale
Risk of competitive clinical data demonstrating superior efficacy/safety, making Tevogen's approach obsolete before commercialization
Large pharma in-house cell therapy programs could capture market share before small biotechs establish commercial presence
Imminent liquidity crisis - current ratio of 0.31 indicates insufficient working capital to meet short-term obligations without immediate financing
Severe dilution risk - 82% stock decline over past year suggests future equity raises will be highly dilutive to existing shareholders at depressed valuations
Going concern risk - auditors may issue going concern warnings if cash runway falls below 12 months without credible financing plan, triggering further stock decline
moderate - Pre-revenue biotechs are partially insulated from GDP cycles as drug demand is non-discretionary, but financing availability is highly cyclical. During recessions, venture capital and public market appetite for speculative biotech diminishes, making capital raises more difficult or dilutive. Clinical trial timelines are generally GDP-insensitive, but partnership activity slows when large pharma companies reduce M&A budgets.
High sensitivity to interest rates through multiple channels: (1) Valuation - pre-revenue biotechs are valued on discounted future cash flows 5-10+ years out, making them extremely sensitive to discount rate changes. Rising rates compress NPV of distant approvals. (2) Financing costs - higher rates increase cost of debt financing and make equity raises more dilutive as investors demand higher returns. (3) Competitive cost of capital - rising rates make safer fixed-income alternatives more attractive versus speculative biotech equity. The 10-year Treasury yield directly impacts institutional allocation to high-risk growth stocks.
Critical exposure to credit market conditions. With negative cash flow, 0.31 current ratio, and no revenue, Tevogen requires continuous access to capital markets for survival. Widening high-yield credit spreads signal risk-off sentiment that typically shuts down biotech IPO/follow-on markets and increases dilution in equity raises. Tight credit conditions could force asset sales, partnerships on unfavorable terms, or bankruptcy if bridge financing unavailable.
momentum/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical events. Not suitable for value investors (no earnings/cash flow to value) or dividend investors (no distributions). Typical holders include biotech-focused hedge funds, retail speculators, and venture crossover funds. The 82% one-year decline and -38% three-month return indicate capitulation by institutional holders, leaving primarily distressed/event-driven players.
high - Clinical-stage biotechs exhibit extreme volatility with 50%+ single-day moves common around data releases. Micro-cap status ($100M market cap) amplifies volatility through low liquidity and wide bid-ask spreads. Implied volatility likely exceeds 100% annualized. Beta to broader market is low (biotech-specific risk dominates), but beta to biotech sector indices is elevated.
